Form D · Biotechnology

EXAGEN INC.

Vista, CA · CIK 0001274737

Offering snapshot reported Feb 1, 2019 · SEC filing

Reported sold
$6.59M
Offering amount: $16M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 2, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 1, 2019Initial$6,586,411No comparison4SEC filing
May 18, 2017Initial$3,749,993No comparison4SEC filing
Apr 10, 2017Initial$1,314,500No comparison5SEC filing
Mar 9, 2017Initial$1,453,000No comparison4SEC filing
Feb 1, 2017Initial$995,889No comparison4SEC filing
Dec 19, 2016Initial$995,889No comparison4SEC filing
Nov 10, 2016Initial$995,889No comparison4SEC filing
Oct 11, 2016Initial$995,889No comparison4SEC filing
Aug 30, 2016Initial$1,000,000No comparison4SEC filing
Jun 24, 2016Initial$2,100,000No comparison6SEC filing
Jan 26, 2016Initial$16,817,541No comparison13SEC filing
Oct 21, 2015Initial$2,999,766No comparison4SEC filing
Jul 6, 2015Initial$3,000,000No comparison3SEC filing
Apr 1, 2015Initial$1,818,767No comparison8SEC filing
Jul 21, 2014Initial$3,950,000No comparison12SEC filing
Oct 15, 2013Initial$5,016,977No comparison11SEC filing
Nov 1, 2012Initial$123,745No comparison5SEC filing
Sep 11, 2012Initial$5,306,834No comparison7SEC filing
Dec 22, 2011Initial$11,986,707No comparison9SEC filing
Nov 18, 2011Initial$1,000,000No comparison4SEC filing
Sep 27, 2011Initial$4,910,423No comparison8SEC filing
Jun 29, 2011Initial$4,910,490No comparison8SEC filing
May 11, 2011Amendment$5,427,984$3,427,989vs Oct 25, 201017SEC filing
Oct 25, 2010Initial$1,999,995No comparison10SEC filing
May 26, 2009Initial$1,000,000No comparisonNot reportedSEC filing
Jul 24, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Apr 23, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Oct 19, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Feb 24, 2006PaperNot reportedNo comparisonNot reportedSEC filing
Jul 11, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-331950

Source: Form D, filed Feb 1, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kamal Adawi Executive
John P. Alsobrook, Ii Executive
John Bessone Director
David Bilvin Director
Brian Birk Director
David Blivin Director
Daniel C. Burrell Director
Lisa Davis Executive
Thierry Dervieux Executive
Scott Glenn Director
Mark Hazeltine Executive
Curtis La Belle Director
Curt La Belle Director
Beto Pallares Director
Ebetuel Pallares Director
Dinesh Patel Director
John M. Radak Director
Sam Riccitelli Director
Fortunato R. Rocca Director, Executive
Ron Rocca Executive
Stephanie Spong Director
Todd Stevens Director
Wendy Swedick Executive
James L.L. Tullis Director
Waneta C. Tuttle Director
Michael Walsh Director
Arthur Weinstein Director
Frank Witney Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1261 Liberty Way Suite C
Vista, CA, 92081